Actinium Pharmaceuticals Inc

NYSE American:ATNMUnited States

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Contact Information

Headquarters

100 Park Ave., 23Rd FloorNEW YORK, NY, United States 10017

Phone

646-677-3870

Fax

845-818-3588

Executives

Chairman of the Board, Chief Executive Officer

Sandesh Seth

Chief Financial Officer

Steve O'Loughlin

Chief Business Officer

Lynn Bodarky

Independent Director

Jeffrey Chell

Lead Independent Director

C. David Nicholson